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 ABSTRACT 
 
 The dystroglycan protein is one of many that attach skeletal muscle fibers to the 
basement membrane at the myotendinous junction. In the alpha-subunit of the dystroglycan 
molecule, there are sugar chains that help with the adhesion of the molecule to the basement 
membrane. A mutation in any gene that codes for an enzyme that adds these sugar chains 
can result in a form of congenital muscle disease called secondary dystroglycanopathy. 
One of the genes that codes for an enzyme that adds sugar chains is GMPPB and a mutation 
in this gene results in GMPPB-associated dystroglycanopathy. Using zebrafish as a model 
for studying dystroglycanopathies has become popular due to their high fecundity, low cost 
of maintenance, and transparency during early developmental stages. We confirmed 
through in situ hybridization that matrix metalloproteinase-13 (mmp13a) is upregulated in 
gmppb mutants and is thought to be a contributor to the progression of the disease. We 
used a mutant gmppb line of zebrafish to see if chemical inhibition of Mmp13 in the 
embryos would rescue the mutant phenotypes. We also used a morpholino knockdown 
strategy when the phenotypes of the gmppb mutants became too variable. We found that 
chemical inhibition of Mmp13 did not rescue either the gmppb mutant or morphant 
phenotype. Based off of our results from these experiments, we can conclude that chemical 
inhibition of Mmp13 does not appear to be a viable treatment for patients diagnosed with 
GMPPB-associated dystroglycanopathy. We also checked to see if there was co-
localization of Mmp13 with macrophages using a fluorescent macrophage reporter 
transgenic zebrafish line and antibody staining for Mmp13 protein. After staining and 
imaging the embryos via confocal microscopy, we did not see any co-localization of 
Mmp13 with macrophages. From the results of this experiment, we can conclude that 
macrophages are likely not the source of Mmp13. 
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 1 
INTRODUCTION 
1. Skeletal muscle: Major Functions and the Form that Enables Those Functions 
Skeletal muscle is one of the three main types of muscle (the other two being 
cardiac and smooth muscle). It is what controls the voluntary movements of the body 
such as walking, running, talking, etc. The muscles you use to perform these actions work 
through contraction of smaller muscle fibers in unison. These fibers are made up of actin 
and myosin filaments which slide past each other, contracting the filaments. Hundreds of 
filaments are arranged together which makes up the individual muscle fiber. When the 
filaments contract, the muscle fiber contracts. The fibers are packed into a muscle bundle, 
which then contracts, followed by the groups of muscle bundles (the muscle itself) 
contracting. Together, all of these fibers and bundles pull on the skeletal system to move 
the body and perform the action needed.  
Along with moving the skeletal system, skeletal muscle performs a variety of 
other functions. Skeletal muscle uses ATP as the energetic molecule for the muscle fibers 
to contract and the muscle to apply the force it needs. During frequent use, such as 
intense exercise, the breakage of ATP produces heat. This production of heat travels to 
the bloodstream where blood temperatures also rise (González-Alonso, Quistorff, 
Krustrup, Bangsbo, & Saltin, 2000). These contractions are controlled by motor neurons 
which send signals to the muscle fibers to contract. Motor neurons can be stimulated by a 
variety of signals. Hormones are heavily involved in the signaling of motor neurons, 
specifically thyroid hormone (TH). TH can be split up into two major hormones, 
triiodothyronine (T3) and thyroxine (T4). T4 increases motor neuron stimulation by 
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rapidly signaling for the activity of Na/K-ATPase, also more commonly known as the 
sodium-potassium pump, to increase in the skeletal myotubes (Bloise, Cordeiro, & 
Ortiga-Carvalho, 2018). This increased activity of the sodium-potassium pump, in 
consequence, increases the transmembrane resting potential of the motor neurons, which 
leads to an increase in the frequency of spontaneously occurring action potentials (Bloise 
et al., 2018). An example of spontaneously occurring action potentials in the skeletal 
muscle is shivering. Shivering is the rapid contraction of the skeletal muscle in the body 
to produce heat when the homeostasis of the body dips below optimal temperatures. This 
is an extremely advantageous adaptation to cold in response to the human body being 
devoid of fur. It is our last line of defense against hypothermia and an important function 
of our skeletal muscle. 
 While the thyroid is an important endocrine organ that has many interactions with 
the skeletal muscle, recent studies have found that skeletal muscle itself may be partly an 
endocrine organ. This was proposed after the discovery of secreted molecules called 
myokines. Myokines are molecules that are secreted by the muscle fibers that have 
autocrine, paracrine, and exocrine function (Huh, 2018). These molecules are important 
to the health and function of the muscle fibers. The autocrine and paracrine effects of 
myokines include the regulation of muscle growth and lipid metabolism, which can help 
provide a feedback loop for muscle adaptation to exercise training; while the endocrine 
function mediates the whole body effects of exercise (Huh, 2018). The endocrine 
function of these myokines also affects the liver, adipose tissue, and bone (Ost, Coleman, 
Kasch, & Klaus, 2016) (See Figure 1). This linkage to other major organs of the body 
shows the importance of the skeletal muscle and how this organ is tied to so many other 
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organs. Further exploration into skeletal muscle and diseases that affect it is of utmost 
importance as the symptoms may extend into many other regions of the body.  
 
Figure 1, taken from Ost et al., 2016: Stress on the skeletal muscle can induce cell 
signaling through the use of myokines. The myokines produced as a result of cellular 
stress are highlighted in red, exercise induced myokines are highlighted in blue, and 
myokines produced by both conditions are highlighted in gray.  
 
While keeping the body at homeostasis is an important characteristic of skeletal 
muscle, the main function of skeletal muscle is to produce the force necessary to move 
the body. The individual muscle fibers are the star players of the contraction. The fibers 
are stretched and placed under immense tension which helps increase the force of 
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contraction. In order for the muscle to pull on the skeletal system, the fibers need to be 
kept under this tension. In order for this to happen, there must be proper connection of the 
fibers to their extracellular matrix (ECM). Improper connection of the fibers can cause a 
variety of symptoms that can lead to great difficulty in doing simple motor movements in 
someone who has muscle fiber attachment problems. When someone has these muscle 
problems, they may not be able to use some or all of their muscles, such as the biceps in 
the arms or quadricep in the leg, normally. When this happens, the muscle fibers become 
weak and shrink in size, with an increase in fiber mortality. This fiber death can be due to 
anoikis – cell death when adhesion to ECM is lost. The shrinking of muscle is called 
muscle atrophy and is a common symptom of many muscle diseases. The process of 
muscle atrophy can be brought on by a variety of stressors that include neural inactivity, 
mechanical unloading, inflammation, metabolic stress, and elevated glucocorticoids 
(Bodine & Baehr, 2014). All of these stressors contribute to symptoms of muscle 
diseases.  
 A common method to combat muscle atrophy is to try and use exercise to build 
and strengthen the muscle. Building of the muscle is called muscle hypertrophy and it has 
been shown to slow the progression of atrophy in muscle disease (Kley, Tarnopolsky, & 
Vorgerd, 2013). People who go to the gym to strengthen their skeletal muscle do so 
through this process. When you go through intense exercise, you put a lot of strain on the 
muscle fibers, which can break them. This is the feeling of being “sore” after a workout. 
Your body recruits amino acids to help rebuild these fibers and protein structures, and 
often produces more of them than before the exercise. Skeletal muscle hypertrophy 
occurs when the rate of muscle protein synthesis from amino acids exceeds that of protein 
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degradation (Goh & Millay, 2017).  
Many of the amino acids that are recruited to repairing the muscle are used to 
build the muscle attachment complexes that anchor fibers to a specific subset of the ECM 
called the basement membrane. These attachments are made through a variety of 
different proteins (See Figure 2). All of these proteins are coded for and produced from 
different genes, for example, dystrophin is coded by the DMD gene and is just one of the 
many different proteins that help the muscle fibers attach to the basement membrane. All 
of these proteins must function correctly in order for this connection to hold and the 
muscle fiber to function properly. Many muscle diseases have been shown to have 
weakened fiber-basement membrane adhesion, especially congenital muscle diseases. 
There are two specific receptor complexes: one is integrin-mediated and the other is 
mediated by the dystrophin-glycoprotein complex (DGC). Both of these receptor 
complexes span from the actin cytoskeleton through the muscle cell membrane to the 
ECM using different adhesion proteins. It is important that all of these “links” in the 
chain are properly attached to each other so that the muscle fibers are able to anchor 
properly.  
Actin is the main component in the cytoskeleton of cells. It is a protein that folds 
flat and has a deep medial cleft that binds ATP which helps attach multiple strands 
together (Pollard, 2016). When these strands bind together, they form long, stiff chains. 
These chains form part of the cytoskeleton and are what give the cell its structure. 
Specifically, in the DGC, dystrophin proteins attach to the actin cytoskeleton. Dystrophin 
proteins (see gray box in Figure 2) are coded for by the human gene DMD. This is one of 
the largest known human genes, containing 79 exons and making up roughly 0.1% of the 
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whole genome (Gao & McNally, 2015). The dystrophin proteins then are bound to 
sarcoglycan proteins, which consist of four transmembrane glycoproteins and respond to 
muscle contractions, transducing mechanical information into a cellular signal (Tarakci & 
Berger, 2016). The next protein structure in the attachment complex is dystroglycan (see 
purple transmembrane protein in Figure 2). There is one gene DAG1 that encodes 2 
subunits (alpha-dystroglycan and beta-dystroglycan) that are formed after post-
translational cleavage of the protein product. Glycosylation of alpha-dystroglycan (see 
light purple chains coming off alpha-dystroglycan in Figure 2) is important in the 
connection between alpha-dystroglycan and laminin in the basement membrane (see 
orange crosses in Figure 2). Laminin is one of the most widely expressed ECM proteins 
(Yao, 2017). It plays critical roles in embryonic development, especially the binding of 
the muscle attachment complex to collagen fibers, the final “link” in the chain. Collagen 
is a triple-helix molecule that exists in many different isoforms in many places in the 
body (Bella, 2016). In the muscle attachment complex, all of these protein structures 
attach to one another, and finally to collagen (see gray wavy proteins in Figure 2), where 
the fiber is secured. When even one of these proteins is not made properly due to a 
mutation that alters its function, the whole complex can fail. When the complex fails, it 
results in a muscle disease, such as muscular dystrophy. Many muscular dystrophies are 
linked to a specific gene that codes for a specific protein, such as Duchenne muscular 
dystrophy resulting from a mutation in the DMD gene, resulting in improper function of 
the dystrophin protein.  
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Figure 2: Cell Adhesion Complexes are Made Through Many Different Proteins, Adapted 
from Goody et al., 2015. Skeletal muscle cell adhesion is done through a variety of 
proteins. All of these proteins are coded for in different genes and a mutation in any one 
of those genes can cause a form of muscular dystrophy. 
 
2. Muscle Disease 
 
Congenital muscle diseases can be caused by mutations in the DNA sequence 
which leads to altered function of the proteins that attach muscle fibers to the basement 
membrane. When this happens, the fibers are likely to break from their attachment. Since 
the fibers are under a lot of tension, they snap back and die, similar to stretching a rubber 
band and then having it break. Common symptoms of congenital muscle disease in 
children are abnormal motor movements such as having trouble with walking. As the 
disease progresses, muscle atrophy, weakening and shrinking of the muscle, is seen and 
sometimes the patient loses the ability to walk or has trouble using their arms. However, 
different muscle groups are affected in different genetic diseases. Some diseases affect 
muscles around the eyes, while others may only affect the muscles in the legs. The most 
common muscle diseases are Duchenne and Becker muscular dystrophy (DMD and 
BMD, respectively), which affect approximately 1 in every 5,500 to 7,700 men (males 
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are more likely to be affected) age 5 to 24 (CDC.gov, 2019) However, any mutation in 
the genes that code for these proteins can cause a different variation of a muscle disease. 
In the case of this study, mutations in the GMPPB gene can cause the protein alpha-
dystroglycan to be post-translationally processed incorrectly, resulting in compromised 
muscle-basement membrane adhesion. Other genetic mutations that can cause congenital 
muscle diseases occur in ITGA7 (integrin alpha 7), LAMA2 (laminin alpha 2), and COL6-
RD (collagen VI) genes. These gene products all function in adhesion complexes that link 
the skeletal muscle fibers to the basement membrane and a problem in just one of them 
can cause a number of disease symptoms.  
Laminin alpha 2 proteins are coded for in the LAMA2 gene and mutations in this 
gene cause a congenital muscular dystrophy called LAMA2 CMD or merosin-deficient 
congenital muscular dystrophy (MDC1A) (Yurchenco, McKee, Reinhard, & Rüegg, 
2018). This form of MD is characterized as early onset and is often very severe. The 
COL6-RD gene codes for collagen VI, an important link in the chain of the muscle 
attachment complex. Mutations in this gene give rise to Ullrich congenital muscular 
dystrophy (UCMD), occurring in 0.13 out of 100,000 individuals, and Bethlem 
myopathy, occurring in 0.77 out of 100,000 individuals (NIH, U.S. Library of Medicine, 
2019) (Butterfield et al., 2017). Patients with either one if these congenital muscular 
dystrophies present with muscle weakness and atrophy along with severe joint 
contractures, joint laxity, and keratosis pilaris (Butterfield et al., 2017). Mutations in 
DAG1 or enzymes that glycosylate alpha-dystroglycan cause a group of muscle diseases 
called dystroglycanopathies. These can be separated into primary and secondary 
dystroglycanopathies. Primary dystroglycanopathies are when there is a mutation in the 
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DAG1 gene, altering the state of the dystroglycan core protein which affects adhesion 
(Brancaccio, 2019.). So far, there are only 3 published reports of primary 
dystroglycanopathy, two of them being siblings (Geis et al., 2013). This project focuses 
on secondary dystroglycanopathies, which are much more common than primary 
dystroglycanopathies. Secondary dystroglycanopathy involves mutations in any gene that 
codes for any enzyme involved in the glycosylation of the alpha-dystroglycan core 
protein. Included in these genes are POMT1, LARGE1, GMPPB, and others.  
 
3. GMPPB and Muscular Dystrophy 
The specific secondary dystroglycanopathy explored in this project results from a 
mutation in the guanosine diphosphate mannose (GDP-mannose) pyrophosphorylase B 
(GMPPB) gene. The result is a form of muscular dystrophy called GMPPB-associated 
dystroglycanopathy. When alpha-dystroglycan is produced, a group of carbohydrate 
chains (O-mannose) are added, which help the protein to be correctly trafficked and 
anchored to the proper basement membrane (Serafini et al., 2018). When alpha-
dystroglycan cannot be trafficked to the right area, or does not obtain these sugar chains, 
the muscle fiber will not be attached properly.  
GMPPB catalyzes the formation of O-mannose carbohydrate chains from GDP-
mannose through O-mannosylation for glycosylating proteins, including alpha-
dystroglycan (Carss et al., 2013). These carbohydrate chains can be seen as finger-like 
projections off of the alpha-dystroglycan molecule (see light purple projections off dark 
purple protein in Figure 2). Mutations that alter the function of the GMPPB gene have 
been shown to lead to hypoglycosylation of alpha-dystroglycan (Carss et al., 2013). 
Those that are affected with this disease have variable phenotypes. The most mildly 
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affected individuals typically have little to no deficiencies in muscle use, while those who 
are severely affected have muscle wasting, intellectual disabilities, and a few have been 
shown to have other disorders such as epilepsy (Jensen et al., 2015). Muscle atrophy is 
the most common symptom of GMPPB-associated dystroglycanopathy. So far, no animal 
model has been generated to study this disease other than zebrafish. Carss et al., 2013 
used a morpholino-mediated knock down zebrafish model and the Henry lab was the first 
to generate a genetic model for GMPPB-associated dystroglycanopathy in zebrafish.  
 
4. Zebrafish as a Model of Study 
Zebrafish (Danio Rerio) have been widely accepted as a useful model for 
developmental biology and genetics experiments. Zebrafish development is rapid, as 
embryos fully develop their major organ systems, including cardiovascular, nervous, 
digestive, and muscle systems, in less than a week (Sarasamma et al., 2017). While they 
develop, the skin is transparent which makes observation and imaging of organ system 
development especially easy and efficient. There is also high fecundity in zebrafish; 
females are able to produce about 50-350 offspring in a week (Steffen et al., 2007). To 
reproduce, zebrafish fertilization is external, which lets the embryos be collected shortly 
after fertilization occurs, providing researchers access to all stages of development. The 
high fecundity and rapid development allow for multiple experimental trials be conducted 
over a relatively short amount of time.  
The cost of maintenance of zebrafish is relatively low as well. The embryos do 
not need food until 4 days post fertilization, which is the conclusion of many experiments 
as their organs have already developed. Different transgenic or mutant lines are also able 
to be purchased for relatively low cost and kept for over 2 years. The small size of the 
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adult zebrafish also allows for multiple fish to be kept in the same tank, reducing the need 
for multiple tanks at large sizes, keeping maintenance costs low.  
Zebrafish are also used as a model of study due to the molecular tools available 
and their genetic amenability. Examination of specific gene function through the 
development of transgenic lines, large scale mutagenesis screens, or antisense gene 
knockdown is highly achievable with zebrafish (Sarasamma et al., 2017). It has been 
shown by the UK Sanger institute that almost 70% of human genes have functional 
homologs in zebrafish, including many of the genes that code for the proteins that attach 
the muscle fiber to the basement membrane (Liu et al., 2017). Genetic and functional 
conservation is important because that means that zebrafish display similar phenotypes 
resulting from the same mutations in their genome as humans. In other words, a mutation 
in a gene that encodes for a protein involved in muscle attachment in a zebrafish will 
produce similar muscle attachment deficiencies as mutations in the homologous human 
genes. 
 Two common methods of investigating gene function in the zebrafish model are 
morpholino-mediated protein knock down and CRISPR/cas9 mutagenesis. Morpholino 
(MO) antisense oligomers are synthetic oligonucleotides that interfere with mRNA 
translation or processing, which results in protein knock down or a “pseudo” mutant 
scenario. Advantages to MOs are that large numbers of “pseudo” mutants can be 
generated for experiments and maternal and embryonic proteins are both knocked down. 
Disadvantages include only temporary protein knock down, injection variability, and off-
target effects (Blum, De Robertis, Wallingford, & Niehrs, 2015). Alternatively, we can 
now relatively easily alter DNA sequences through CRISPR/cas9 mutagenesis. This 
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system allows genome editing of different species using specific RNA segments and the 
Cas9 enzyme to cut the target DNA sequence and replace it with a customized DNA 
sequence (J. Liu et al., 2017). Research labs and institutes are using this technique to 
create mutant lines of zebrafish to model different genetic diseases, including the Henry 
lab where they used CRISPR mutagenesis in an attempt to make genetic models for 16 
dystroglycanopathies.  
There have been valuable clinical outcomes from zebrafish research, including a 
MO drug that was approved by the FDA for treatment of DMD in September 2016. The 
drug is called eteplirsen and it employs the use of antisense oligonucleotides to interfere 
with pre-mRNA splicing of DMD, which excludes the specific exon targeted (Lim, 
Maruyama, & Yokota, 2017). While this interference with DMD splicing was shown only 
to delay the disease progression slightly, it is a step in the right direction for the use of 
MOs in human clinical trials. With more exploration and resources aimed at these drugs, 
treatment of congenital diseases, such as DMD, could be developed with MO drugs. 
Basic research with MOs and CRISPR mutagenesis in zebrafish and other model 
organisms is really what made this drug possible. Being able to model human diseases in 
animals not only gives us a closer look into how diseases work, but also how to treat 
them.  
 
5. Zebrafish Muscle Development 
The development and physiology of skeletal muscle in zebrafish shares many 
commonalities with higher vertebrates, including mammals such as mouse and dog 
models (Goody, Carter, Kilroy, Maves, & Henry, 2017). However, there are differences 
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in the skeletal muscle of zebrafish compared to higher vertebrates that can be viewed as 
experimental advantages. In zebrafish, the different muscle fiber types, fast-twitch vs 
slow-twitch, are spatially segregated. This allows for the observation of fiber-type 
specific effects when experimenting while also providing an opportunity for identifying 
the mechanisms that regulate fiber-type specification (Goody et al., 2017). Development 
of the muscle is also easily observed. Skeletal muscle development in zebrafish is rapid 
and completed in a few days. The muscle originates from somites with somitic cells as 
the precursors to the individual fibers. These precursor cells elongate and eventually 
become the actual muscle fibers, which are then separated into segments called 
myotomes (See Figure 3) (Snow, Peterson, Khalil, & Henry, 2008). These myotomes are 
characterized by having a sideways “V” shape, also known as a chevron, with an angle of 
approximately 90º.  
Figure 3: The Development of Skeletal Muscle from Somites: Adapted from Goody, 
Carter, Kilroy, Maves, & Henry, 2017. The development of skeletal muscle starts with the 
somite (pictured on the right) which contains short-precursor cells. These cells elongate, 
attach to ECM, and then form the multinucleated striated skeletal muscle fibers within 
the myotome (pictured to the left).  
The lines that separate the individual myotomes are the myotendinous junctions 
(MTJs). This is the site of attachment for the individual muscle fibers. The same proteins 
involved with human muscle fiber attachment are also involved with fiber attachment in 
zebrafish.  
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6. Zebrafish Models of Muscle Disease 
 Zebrafish have been used to model muscle disease, including muscular dystrophy 
and dystroglycanopathy, across the world. They are one of the smallest models of muscle 
disease used today. Dystrophin-deficient zebrafish, a model of DMD, are especially 
useful for large-scale drug discovery screens, as they share characteristic morphological, 
physical, and genetic features with mammals, but also have high fecundity and rapid 
development (Widrick et al., 2016). For example, it was found that the chemical 
aminophylline, was able to restore muscle structure in dystrophin deficient DMD 
zebrafish mutants (Kawahara & Kunkel, 2013). Merosin-deficient congenital muscular 
dystrophy (MDC1A), a laminin-associated muscular dystrophy, has also been modeled in 
zebrafish. Laminin chains have major signaling functions in skeletal muscle, so altering 
the structure of this molecule could have major consequences on muscle development 
and structure (M. Li & Arner, 2015). Being able to model this in the zebrafish is 
especially helpful in attempting to treat this form of muscular dystrophy. Studies in the 
zebrafish MDC1A model showed that muscle fibers detach from the basement membrane 
before cell death occurs, which is different than in the zebrafish DMD model where cell 
death occurs before detachment (Hall et al., 2007). A severe form of muscular dystrophy, 
Ullrich congenital muscular dystrophy (UCMD), has been modeled in zebrafish via MO 
knock down of collagen VI. The model has let us obtain a better understanding on how 
collagen VI is involved in this form of MD (Radev et al., 2015).  
 With new techniques in mutagenesis and as zebrafish rise in the ranks as models 
of studying muscle disease, we are able to look at muscle development and disease under 
an entirely different light. We have learned so much not only about the underlying causes 
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of muscle disease, but we have connected the physiological consequences to the genetic 
alterations that cause these diseases. It is a long path until we are able to treat these 
diseases, but we come closer and closer every day.  
 
7. The Thesis Project 
In GMPPB-associated dystroglycanopathy, a mutation in the GMPPB gene will 
cause hypoglycosylation of the alpha-dystroglycan protein. In our zebrafish GMPPB-
associated dystroglycanopathy model generated with CRISPR/cas9 mutagenesis, we find 
muscle disease is characterized by two distinct characteristics: broken muscle fibers 
within the myotome and crossing of muscle fibers over the MTJ. From a transcriptomics 
screen, we found an upregulation of matrix metalloproteinase 13 (mmp13) at the RNA 
level in gmppb mutant zebrafish leading us to hypothesize that Mmp13 plays a role in 
causing these two muscle phenotypes. MMPs are a group of enzymes that are involved 
with the breakdown of the ECM and tissue remodeling (Pasiakos, Lieberman, & 
McLellan, 2014). If a mutation in the gmppb gene is causing an upregulation of mmp13, 
the protein could also be upregulated. Being an ECM and tissue remodeling enzyme, this 
protein could be breaking down parts of the muscle attachment complex, or muscle ECM.  
This project is a characterization of one of the CRISPR models of secondary 
dystroglycanopathy, GMPPB-associated dystroglycanopathy. Specifically, we studied the 
role of mmp13 upregulation in these gmppb mutated zebrafish. We used chemical 
inhibition of Mmp13 in the mutants and morphants to see if we could prevent the two 
main symptoms of the disease: broken muscle fibers and MTJ boundary crossings. We 
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hypothesized that the inhibition of Mmp13 would lead to a “rescue” of these gmppb 
phenotypes.  
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MATERIALS AND METHODS 
 
1. Zebrafish Strains, Care, and Maintenance 
Adult zebrafish were kept at 28.5 ºC on a 16 h light/8 h dark cycle. Zebrafish 
embryos were collected from natural spawning of these adult fish. Embryos were staged 
according to Kimmel, Ballard, Kimmel, Ullmann, & Schilling, 1995. Experiments were 
conducted with the approval of the University of Maine Institutional Animal Care and 
Use Committee (IACUC). Embryo Rearing Media (ERM) was made in a 1 L bottle with 
0.3 g NaHCO3, 50 mL 20x ERM stock, and brought to 1 L with ddH2O. Two drops of 
methylene blue were added after the ddH2O. The wild-type lab strain of zebrafish used 
was AB. The macrophage transgenic line was from by Pagán et al., 2015. The gmppb 
mutant line was generated by the Henry Lab at the University of Maine. 
 
2. CRISPR Mutagenesis 
CRISPR/cas9 mutagenesis was performed as described in Gagnon et al., 2014. 
Injected zebrafish (F0 generation) were grown to adulthood and identified as carriers of 
gmppb mutations via PCR for the inserted stop codon cassette or through pair-wise 
spawns that produced embryos with abnormal phenotypes. Experiments in this thesis 
involved spawning F2 adult gmppb mutant carriers and analyzing the F3 generation of 
embryos. 
 18 
 
3. Morpholino (MO) injections 
MOs were purchased from Gene Tools, LLC and injected as in Carss et al., 2013, 
except that p53 MO was not used. 3 ng of MOs was injected into each embryo at the 1-4 
cell stage. MOs were injected with a MPPI-2 Pressure Injector from ASI. 
  
4. In situ Hybridization 
 In situ hybridization (ISH) was performed as described in Jowett, 1999. Briefly, 
embryos were dechorionated and put in 4% paraformaldehyde (PFA) for 4 hours at room 
temperature or overnight at 4 ºC. The embryos were then washed 5 times for 5 minutes 
each with Phosphate Buffer Saline (PBS) with 0.1% tween-20. The embryos were 
incubated in prehybridization solution (50% Formamide, 5x sodium chloride-sodium 
citrate buffer, 50 μg/mL Heparin, 500 μg/mL Yeast tRNA, 0.1% tween20, pH of 6.0 with 
citric acid) for 4 hours at 65 ºC, and then hybridized at 65 ºC overnight with a 
digoxygenin-labeled probe. Embryos were washed using serial dilutions into and out of 
2x saline-sodium citrate (SSC), then incubated in anti-digoxygenin Ab (Roche) for 2 
hours at room temperature, washed, and then developed in 0.45% NBT/0.35% BCIP 
(Roche) until the embryos reached the desired color. The developing process was stopped 
by fixing with 4% PFA or rinsing 4 times in sterile water. The probe was designed to 
hybridize to zebrafish mmp13a and had a forward primer sequence of: 5’-TGG TGA 
GAA ACG TTC CAG CGA TGT-3’ and a reverse primer sequence of (including the t7 
bacterial promoter sequence): 5’-GTA ATA CGA CTC ACT ATA GGG CAC TCT TGG 
GAT AGC CTT GCA CCA T-3’.  
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5. MMP13 Inhibitor Experimental Setup 
MMP13 inhibitor (CL82198 – 10 mg) was purchased from TOCRIS. It was 
dissolved in DMSO to 10mM, aliquoted, and stored at –20 ºC. Zebrafish were exposed to 
10 uM MMP13 inhibitor diluted in 1X ERM. All treatments were set up with 5 mL ERM 
in 25 mL petri dishes with the addition of 5 μL solution if applicable (dose taken from 
(Lisse et al., 2016). The embryos were dechorionated at 1 dpf and separated based on 
whether they were wild type, had a subtle phenotype, or a severe phenotype, then placed 
in the proper treatment. There were three setups for the treatments: 1) The controls, 
having 5 mL ERM, 2) The MMP13 inhibitor group having 5 mL of ERM with 5 μL of 
the MMP13 inhibitor stock solution, and 3) DMSO control group having 5 mL ERM with 
5 μL of DMSO added. Each solution was discarded and replaced approximately every 24 
hours until 4 days post fertilization (dpf). Any dead embryos (determined by having no 
heartbeat) were removed if necessary every time the solution was changed. At the end of 
4 dpf, the fish were removed from the treatments, fixed, and stored to be prepared for 
staining.      
 
6. Fixation 
The embryos were placed in 4% paraformaldehyde for 4 hours at room temp or 
overnight at 4 ºC. They were then washed out 3 times rapidly with PBS 0.1% Tween. The 
embryos were then stored in PBS 0.1% Tween at 4 ºC until it was time to perform 
immunohistochemistry. 
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7. Immunohistochemistry 
 After the embryos were fixed, they were washed with decreasing volumes of PBS 
0.1% Tween rapidly 3 times. The embryos were then put in 2% triton PBS and rocked for 
1.5 hours at room temperature. They were then rinsed 2x quickly with PBS 0.1% Tween 
and 20 μL of a 1:20 ratio of phalloidin 546 to PBS 0.1% Tween was added to each tube 
and the tubes were kept under foil at 4 ºC overnight. The embryos were rinsed with PBS-
tween and rocked 5 rounds for 5 minutes. Antibody (AB) block was added to the tubes 
for one hour and then replaced with a 1 μL primary antibody to 200 μL AB block dilution 
and kept at 4 ºC overnight. Primary antibody was removed and replaced with AB block 
for approximately 8 hours at room temperature. The polyclonal secondary antibody was 
then put in at a 1 μL to 200 μL ratio to AB block and kept at 4 ºC overnight. Then the 
antibody was pipetted out and 0.1% tween was added. The embryos were then stored in 4 
ºC until ready to be deyolked and mounted. The MMP13 hinge primary antibody was 
purchased from Anaspec and secondary, fluorophore-conjugated antibodies were 
purchased from Molecular Probes. 
  
8. Deyolking and Mounting 
 The yolk of the embryos was removed in PBS using insect pins superglued into 
glass capillary tubes and 2-5 embryos were mounted on a microscope slide in 80% 
glycerol/20% PBS and covered with a cover slip held up by vacuum grease feet. 
 21 
 
9. Imaging 
After fixation, immunohistochemistry, deyolking, and mounting, the embryos 
were imaged on a Leica confocal DMi8 with a 10x/0.40 HC PL APO objective. 
Maximum projections of z-stacks were generated and then the images were analyzed. 
Images were pseudo-colored and merged in Adobe Photoshop. 
 
10. Data Analysis 
After images of the fish were taken, they were analyzed for two types of data. 1) 
The number of broken fibers and MTJ boundary crossings were counted. The percent of 
myotome segments with a broken fiber per embryo and boundary crossings per embryo, 
along with the average of those percentages were then calculated. The percentages of 
each were then graphed. 2) The images were checked for co-localization of Mmp13 
protein and fluorescent macrophages.  
 
11. Statistical Analyses 
 The averages and standard error of the mean of the data collected were calculated 
and graphed using GraphPad Prism 7. T-tests and ANOVA of the above data were also 
calculated for statistical significance through GraphPad Prism 7.  
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RESULTS 
1. In situ Hybridization Confirms mmp13a Upregulation 
Preliminary RNA-sequence data showed that zebrafish isoforms of mmp13 were 
upregulated in 4-day old gmppb mutants compared to wild-type siblings. To determine 
the spatial location of mmp13 upregulation in the gmppb mutants, we performed in situ 
hybridization (ISH) in 4-day old gmppb mutants and wild-type siblings. An antisense 
probe was made to compliment a 500 bp region of zebrafish mmp13a. In 2 experiments, 
we saw upregulation of mmp13a in the ventral, medial region of myotomes in cells with a 
morphology and location suggesting they could be white blood cells. These data confirm 
the RNA-sequence data and suggest that mmp13a upregulation in gmppb mutants is due 
expression in some type of white blood cell localized in the ventral, medial region of the 
body (See purple dots in Figure 4).   
  Because we saw upregulation of mmp13a in mutants relative to wild-types at 4 
dpf, we performed ISH for mmp13a at earlier timepoints to determine when the mutants 
first begin to express more mmp13a than wild-types. We performed mmp13a ISH on 2, 3 
and 4-day old gmppb mutants and wild-type siblings. At 2 dpf, both wild-types and 
gmppb mutants showed mmp13a expression in what we believed to be white blood cells 
in the ventral, medial trunk (Figure 5 top panels). At 3 dpf, mmp13a expression was 
absent in the trunk of wild-types yet remained expressed in gmppb mutants (Figure 5 
bottom panels). Therefore, mmp13a was found to be upregulated at 3 dpf in gmppb 
mutants compared to wild-types. A similar upregulation of mmp13a was again seen in 4-
day old gmppb mutants compared to wild-types. Normally, Mmp13a is silenced starting 
around 3 dpf, however this is not the case for gmppb mutants. These results suggest that 
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mmp13a expression is upregulated beginning at 3 dpf in presumptive white blood cells in 
gmppb mutants compared to wild type siblings.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: in situ hybridization results of gmppb mutants compared to wt controls at 4 dpf. 
ISH shows that mmp13 (indicated as purple dots shown by the red arrow) is upregulated 
in 4 dpf gmppb mutant (bottom) as compared to the wild type (top). 
 
 
 
 
WT 
 
 
 
 
 
 
 
 
gmppb 
Figure  SEQ Figure \* ARABIC 4: in situ hybridization results of 
gmppb mutants compared to wt controls at 4 dpf. ISH shows that 
mmp13 (indicated as purple dots shown by the red arrow) is 
upregulated in 4 dpf gmppb mutant (bottom) as compared to the wild 
type (top).  
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Figure 5: in situ hybridization results of gmppb mutants compared to wt controls at 2 dpf 
and 3 dpf. ISH shows that mmp13 (purple dots) is present in both the wild type and the 
gmppb mutants at 2 dpf. It is not present in the wild type, however, at 3 dpf while gmppb 
mutants show the presence of mmp13 at 3 dpf. 
 
2. Chemical Inhibition of Mmp13 Does not Rescue gmppb Mutants 
Next, we sought to determine the functional consequence of mmp13 upregulation 
on the muscle phenotype of gmppb mutants using a chemical inhibitor of Mmp13 protein 
at a dose previously shown to have an effect in zebrafish (Lisse et al., 2016). Gmppb 
mutants have been shown to have two main muscle phenotypes along with upregulated 
mmp13: fiber breakage and/or MTJ boundary failure. To see if we could reduce the levels 
of fiber breakage and MTJ crossovers, we used a chemical inhibitor to block the activity 
of the Mmp13 protein. The images taken and analyzed from the confocal microscope 
showed that there were similar levels of both broken fibers (see embryo pictures in Figure 
6 and image quantification in Figure 7) and boundary crossings in gmppb mutants (see 
embryo pictures in Figure 8 and image quantification in Figure 9) that were untreated, 
DMSO treated, or Mmp13 inhibitor treated. These data do not support the hypothesis that 
Figure  SEQ Figure \* ARABIC 5: in situ hybridization results of gmppb mutants 
compared to wt controls at 2 dpf and 3 dpf. ISH shows that mmp13 (purple d ts) is 
present in both the wild type and the gmppb mutants at 2 dpf. It is not present in the wild 
ty e, however, at 3 dpf while gmppb mutants show the presenc  of mmp13 at 3 dpf. 
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chemical inhibition of Mmp13 reduces the amount of fibers that break or cross 
boundaries in gmppb mutants.  
 
Figure 6: Fiber breakage is not reduced in gmppb mutants through chemical inhibition 
of mmp13. Fiber breakages in gmppb mutants for the untreated controls (A), DMSO 
controls(B), and MMP13 inhibitor group (C) are characterized by a brighter spot in the 
myotome. Broken fibers are indicated by a red arrow. From this data, we can conclude 
that inhibition of MMP13 does not reduce fiber breakage in gmppb mutants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Graph showing the percent of myotomes per embryo with a broken fiber in 
gmppb mutants with the mean and standard error of the mean. The average percent of 
the untreated controls, DMSO controls, and Mmp13 inhibitor group were 13.07, 10.48, 
and 11.43, respectively. The results from an ANOVA test for untreated vs DMSO was 
0.77, untreated vs Mmp13 inhibitor was 0.97 and for DMSO vs Mmp13 inhibitor was 
0.94. These p-values do not imply statistical significance. These results do not support 
our hypothesis that chemical inhibition of Mmp13 would reduce the fiber breakage in 
gmppb mutants.  
 
Figure  SEQ Figure \* ARABIC 6: Fiber breakage is not reduced in gmppb mutants through 
chemical inhibition of mmp13. Fiber breakages in gmppb mutants for the untreated controls 
(A), DMSO controls(B), and MMP13 inhibitor group (C) are characterized by a brighter spot 
in the myotome. Broken fibers are indicated by a red arrow. From this data, we can conclude 
that inhibition of MMP13 does not reduce fiber breakage in g ppb mutants. 
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Figure 8: MTJ boundary crossings boundary crossings are not reduced in gmppb 
mutants. MTJ boundary crossings in the untreated controls (A), the DMSO controls (B), 
and the MMP13 inhibitor group (C) are indicated by the red arrows. From this data, the 
inhibition of MMP13 did not lead to a decrease in boundary crossings in gmppb mutants. 
 
 
Figure 9: Graph showing the percent of myotomes with an MTJ failure in gmppb mutants 
with the mean and standard error of the mean. The average percent of the untreated 
controls, DMSO controls, and Mmp13 inhibitor group were 17.89, 15.76, and 13.42, 
respectively. The p-values from an ANOVA test for untreated controls vs DMSO controls, 
untreated controls vs the inhibitor group, and the DMSO controls vs the inhibitor group 
were all 0.99 which does not imply statistical significance. These results do not support 
our hypothesis that chemical inhibition of Mmp13 would reduce MTJ failure in gmppb 
mutants. 
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3. Mmp13a is Upregulated at 4 dpf in gmppb Morphants Compared to Controls 
The results of the figures and the images taken from the microscope showed us 
that chemical inhibition of Mmp13 did not slow the progression of the 
dystroglycanopathy in gmppb mutants. However, the spawns of gmppb mutants were 
variable, as some had worse phenotypes than others and some seemed like they had no 
phenotypes at all. Because of this, we sought to use MOs to knock down Gmppb. First, 
we confirmed through ISH that mmp13a is upregulated in gmppb morphants at 4 dpf and 
saw a similar upregulation and expression pattern for mmp13a in gmppb morphants 
compared to un-injected controls as we did in the gmppb mutants (data not shown). 
 
4. Chemical Inhibition of Mmp13 Does Not Rescue gmppb Morphants 
 Now that upregulation of mmp13a at the RNA level is confirmed in gmppb 
morphants, we sought to use chemical inhibition of Mmp13 with these morphants to see 
if we could slow the progression of the muscle disease through the reduction of fiber 
breakages and MTJ failures. We repeated the previous experiments we did with the 
mutants with the morphants and analyzed for the same results. Gmppb morphants treated 
with Mmp13 inhibitor did not display fewer broken fibers than untreated gmppb 
morphant controls or DMSO treated gmppb morphant controls (see Figure 10 for image 
quantification data).   
When analyzing the images, the morphant myotomes were mostly too poorly 
organized to properly see if the muscle fibers crossed the MTJ. We did not want to make 
any false inferences when extracting this data, so we did not analyze the images for MTJ 
crossings.  
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Figure 10: Graph showing the percent of myotomes per embryo with a broken fiber in 
gmppb morphants with the mean and standard error of the mean. The average percent of 
the untreated controls, DMSO controls, and Mmp13 inhibitor group were 16.11, 11.32, 
and 20.79, respectively. The results from an ANOVA for the untreated controls vs the 
DMSO controls was 0.71, the untreated controls vs the inhibitor group was 0.78, and the 
DMSO controls vs the inhibitor group was 0.43. These results do not imply statistical 
significance. These results do not support our hypothesis that chemical inhibition of 
Mmp13 would reduce fiber breakage in gmppb morphants. 
 
5. Mmp13 Protein Does Not Appear Upregulated in gmppb Morphants 
One possible explanation for the chemical inhibitor not having an effect on either 
the gmppb mutants or morphants would be that there was no upregulation of Mmp13 at 
the protein level. ISH only showed us that mmp13a is upregulated at the RNA level. Our 
chemical inhibitor would only be effective at preventing the activity of Mmp13 protein.  
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To determine if Mmp13 was upregulated at the protein level, we used 
immunohistochemistry to antibody stain for Mmp13 protein level expression using an 
anti-MMP13 hinge antibody from Anaspec. One small preliminary experiment showed 
that there was Mmp13 staining in cells that, based on location and morphology, appear to 
be red and white blood cells. This staining pattern was seen in both controls and gmppb 
morphants and did not appear upregulated in gmppb morphants relative to controls (see 
Figure 11).  
 
6. Mmp13 Protein Does Not Co-localize with Macrophages 
We also used immunohistochemistry to see if there was co-localization of Mmp13 
with macrophages. We used Tg(mpeg1:GFP) fluorescent transgenic zebrafish (Pagán et 
al., 2015) injected with gmppb MOs to observe whether Mmp13 protein and fluorescent 
macrophages co-localize. In one small preliminary experiment, we found that there was 
not exact co-localization of Mmp13 and macrophages in either the morphants or the 
controls (See Figures 11 and 12). Mmp13 protein seemed to be located adjacent to the 
macrophages. Macrophages could be producing the Mmp13 and then secreting the 
protein out into the ECM. However, if there was secretion from macrophages, we would 
still expect to see some Mmp13 protein co-localize with macrophages. 
 
Figure  SEQ Figure \* ARABIC 11: Staining for mmp13 and macrophages does not show co-
localization in the wt control trunk or tail. The stain for macrophages (left) and mmp13 antibody 
(middle) was merged (right) to see if there was any co-localization of mmp13 and macrophages. 
From the images taken, we did not see co-localization of mmp13 and macrophages in the wt 
controls.  
Figure 12: Staining for mmp13 and macrophages does ot show co-localization in gmppb morphant 
trunk or tail. The stai  for macrophages (left) nd mmp13 (middl ) was merged (right) to see if there 
would be any co-localization of mmp13 and macrophages. Fr m the i ages taken, we did not see co-
localization of mmp13 an  macrophages in gmppb morphants.  
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Figure 11: Staining for mmp13 and macrophages does not show co-localization in the wt 
control trunk or tail. The stain for macrophages (left) and mmp13 antibody (middle) was 
merged (right) to see if there was any co-localization of mmp13 and macrophages. From 
the images taken, we did not see co-localization of mmp13 and macrophages in the wt 
controls. 
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Figure 12: Staining for mmp13 and macrophages does not show co-localization in 
gmppb morphant trunk or tail. The stain for macrophages (left) and mmp13 (middle) was 
merged (right) to see if there would be any co-localization of mmp13 and macrophages. 
From the images taken, we did not see co-localization of mmp13 and macrophages in 
gmppb morphants. 
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DISCUSSION 
 The results of RNA-seq and ISH showed us that there is an upregulation of 
mmp13a in the gmppb mutants and morphants at the RNA level. This upregulation, we 
believed, could be a contributor to the progression of GMPPB-associated 
dystroglycanopathy, and inhibition of Mmp13 would be able to rescue the mutants and 
morphants. However, from the results of the experiment, we can see that chemical 
inhibition of Mmp13 does not rescue the phenotype of either the gmppb mutants or 
morphants like we had previously believed it would.   
Throughout the course of these experiments, we encountered issues with our 
animal models. The variability in phenotypes of the gmppb mutants was a large issue 
with the first part of the experiment. We were unable to take the genotype of each 
individual embryo in each treatment due to lack of time and resources, so we relied on 
phenotypic sorting. Without the genotype, we were not able to confirm whether or not the 
embryo had the specific mutation in the gmppb gene. Using MO injections was the next 
option, as we had already confirmed the upregulation of mmp13a at the RNA level in 
gmppb morphants. However, the phenotypes of the morphant were much more severe 
than that of the mutants. This could be due to the fact that MO knockdown of gmppb 
blocks both maternal gene products and embryonic gene products, while the mutant 
embryos only had their embryonic gene products altered. When an embryo is developing, 
maternal RNA produces many of the gene products that are crucial for this development. 
Once the maternal RNA runs out, then embryo starts producing its own gene products. A 
mutation in the embryo will not show a phenotype until the embryo’s maternal RNA 
degrades and the embryonic RNA starts being used. When using MO knockdown, both 
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the RNA from the mother and the embryonic RNA is blocked. This, in consequence, 
could lead to a worse phenotype in the morphant (if gmppb is maternally expressed), as 
the gmppb gene is blocked right at the start of development. Another possibility for the 
discrepancy between morphant and mutant phenotypes is that the gmppb mutation (which 
we think is a hypomorphic scenario) could result in more functional Gmppb protein than 
in the morphant. Overall, being able to combat the variability in the gmppb mutants or 
reducing the severity of the gmppb morphant phenotype would be key in improving this 
experiment and solidifying our results. 
 While we were clearly able to observe the consequences of the mutated gmppb 
gene and the MO knockdown, the chemical inhibitor was not able to rescue the embryos 
affected with the disease. There are a couple of possibilities for the inhibitor not working. 
One of the reasons is that the chemical inhibitor only inhibits Mmp13 activity at the 
protein level, and we were only able to confirm upregulation of mmp13 at the RNA level. 
There is a possibility that the protein was not translated from the mmp13 RNA. 
Differences in protein vs mRNA levels have been seen before. Liu et al., 2016 showed 
that there is a heavy influence in the relationship between protein levels and their coding 
transcripts as a result of the temporal and spatial variations of mRNAs, as well as the 
local availability of resources for protein biosynthesis. While it is possible that there are 
varying levels of RNA vs protein, I couldn’t find an example of the protein not being 
produced while the RNA is upregulated in the current literature. This makes it more 
likely that using Mmp13 inhibition as a way to treat GMPPB-associated 
dystroglycanopathy may not be a worthwhile method. 
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 There is also the possibility, if Mmp13 protein was in fact upregulated, that we 
added the chemical inhibitor at the incorrect time and/or dose to be able to inhibit the 
Mmp13 protein. We determined the dose and time of administration from Lisse et al., 
2016, as their study found that this dose and time produced significantly different results 
in axon regeneration in zebrafish. To see if this dose worked in our study, we would have 
to conduct an experiment that tested different doses at different stages of development. 
We did not perform this trial before our experiment because we did not have the time or 
the resources to perform this and the actual experiments in the academic year.  
 Another factor that would preclude the chemical inhibitor from rescuing the 
GMPPB-associated dystroglycanopathy muscle phenotype is that there may have been 
earlier developmental processes that were disrupted before we added the chemical 
inhibitor. If even just one process did not take place normally, this could cause a whole 
cascade of consequences. If this was the case, there would not be anything we could do to 
control it unless we could identify the developmental process that was affected in the first 
few hours of development. However, we don’t believe this to be the case because 
mmp13a was normally expressed in both wild type and gmppb mutants at 2 dpf and the 
only difference in gene expression was detected at 3 and 4 dpf. We added the Mmp13 
inhibitor at 1 dpf, which was a developmental stage prior to when mmp13 expression 
became different. 
When analyzing the images for co-localization of Mmp13 and macrophages, we 
found that there was none. While the Mmp13 staining had a morphology consistent with 
macrophages, the Mmp13 was adjacent to but not overlapping with any transgenic 
fluorescent macrophages. One hypothesis for this is that the Mmp13 protein could have 
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been secreted by a nearby cell. This is unlikely, however, as the antibody we used stains 
the hinge region of the Mmp13 protein, which is present in both the proenzyme and the 
mature enzyme. If it was the macrophages that were secreting Mmp13, we would be able 
to see the proenzyme stained within the macrophages. There could be other cells in the 
area that could be secreting Mmp13, so we would need to stain for other cell types and 
see which ones co-localize with Mmp13 protein. One possibility could be that neutrophils 
are secreting Mmp13. Neutrophils are another type of white blood cell that resides with 
macrophages in the zebrafish embryo during this stage. We would need to use antibody 
staining or a fluorescent transgenic line to visualize neutrophils and stain for Mmp13 
protein as well. If we see co-localization of Mmp13 and neutrophils, we would be able to 
confidently suggest that these are the cells secreting the Mmp13 protein. Mmp13 has 
been shown to be secreted by neutrophils as well as macrophages (Lin, et al., 2015). 
Dendritic cells and mast cells have also been shown to produce Mmp13 under certain 
circumstances (X.-D. Li et al., 2017), (Lin, Yeh, Li, & Chang, 2015). 
 There are many aspects of this experiment that could be modified if we decide to 
explore this topic further. First, taking the genotype of the gmppb mutants would allow us 
to be able to confidently identify which embryos have received the mutation and we 
would not have to rely on observing the phenotype of the embryo. This rules out the 
possibility that the fish may have had a developmental issue that looked as though they 
were affected by the disease, which could also help alleviate the variability we observed 
in the mutants. Being able to take out the embryos that are not affected by the disease 
would save time and money, as we wouldn’t be treating any embryos that were not 
gmppb mutants.  
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 Instead of using a chemical inhibitor to block the activity of Mmp13, it would be 
advantageous to be able to genetically inhibit mmp13. We could use CRISPR/Cas9 to 
create a mutant line of mmp13 mutant zebrafish. However, zebrafish have 2 isoforms of 
mmp13 and we would have to cross these mutant lines to the gmppb mutant line. This 
would require a triple mutant line, which would take a long time to raise to sexual 
maturity for spawning and the odds of getting triple mutant embryos would be 1:64.  
 Another way the experiment could be improved upon would be to test for co-
localization of Mmp13 and neutrophils or other white blood cell types. To view the 
neutrophils, we could use a transgenic line of zebrafish that shows fluorescent 
neutrophils. Staining for Mmp13 would show us whether there was co-localization of 
Mmp13 and neutrophils, which would help us answer the question of where the Mmp13 
is coming from. If there is no co-localization, we would have to continue to find a cell 
type that co-localizes with Mmp13 protein.  
 To improve the experiment, we could also run trials to determine whether or not 
the dose of the inhibitor and the time it was administered were effective. We tried to 
model the inhibitor administration after a human clinical trial, as a patient wouldn’t be 
given a drug until the doctor is able to see the phenotype and obtain the genotype to 
confirm the presence of GMPPB-associated dystroglycanopathy.  
 While ISH showed us that mmp13a is upregulated in gmppb mutant zebrafish, we 
were not able to rescue either the gmppb mutants or the morphants through chemical 
inhibition of Mmp13. This shows that this chemical inhibition of the protein may not be a 
viable way of treating this disease. However, improvement of our experiment and further 
exploration of possible treatments for GMPPB-associated dystroglycanopathy would 
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enhance our understanding of the disease, the underlying mechanisms, and the symptoms 
to hopefully move towards better treatment options in the future.  
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